Related Experiment Videos
Clinical experience with intravenous granisetron
1Department of Medical Oncology, Royal Infirmary, Glasgow, UK.
Anti-Cancer Drugs
|June 1, 1994
Summary
Granisetron, a potent 5-hydroxytryptamine3 (5-HT3) antagonist, effectively manages chemotherapy-induced emesis. This advance offers better antiemetic control for patients undergoing high-dose chemotherapy.
Area of Science:
- Oncology
- Pharmacology
Background:
- High-dose chemotherapy improves tumor response and survival but necessitates effective antiemetic control.
- Chemotherapy-induced emesis remains a significant challenge for patients undergoing cancer treatment.
Purpose of the Study:
- To review the development and application of 5-hydroxytryptamine3 (5-HT3) antagonists, focusing on granisetron.
- To highlight granisetron's efficacy in managing chemotherapy-induced emesis.
Main Methods:
- Review of scientific literature on 5-HT3 antagonists and granisetron.
- Comparison of granisetron's potency and side effect profile with metoclopramide.
Main Results:
- Granisetron is a potent 5-HT3 antagonist, significantly more effective than metoclopramide.
- Granisetron demonstrates efficacy as a single prophylactic dose, over 5 days, and in repeated chemotherapy cycles.
- Granisetron effectively controls breakthrough nausea and vomiting, with no extrapyramidal side effects.
Conclusions:
- Granisetron represents a significant advancement in controlling chemotherapy-induced emesis.
- Effective antiemetic control is crucial for patients receiving high-dose chemotherapy.
- Granisetron offers a superior safety and efficacy profile for managing emesis.